tirzepatide and hydroxychloroquine Microdose Novartis leaps into hydroxychloroquine fray

This helpful tool tracks your response to GLP-1 medications, allowing you to manage side effects, adjust dosing, and determine when to stop treatment based on your personal experience

Forum posts share personal experiences, often without medical records, product verification, lab results, or follow-up details

Treating Facial Volume Loss With Fillers For patients who want to restore lost volume and droopy skin, and rejuvenate their appearance, dermal fillers offer a safe, effective, and non-surgical solution

A pre-specified indirect comparison analysis of matched patient-level data from the REWIND and SURPASS-CVOT studies found tirzepatide reduced the risk of MACE by 28%, and all-cause mortality by 39% compared to a placebo

No generic formulas or rushed plans, only a tailored strategy rooted in data and what your body needs